Page last updated: 2024-10-22

amantadine and Depression

amantadine has been researched along with Depression in 44 studies

amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

ExcerptRelevanceReference
"Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months."7.65Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972)
"Amantadine was not superior to placebo."6.72Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006)
"Amantadinesulfate is a well known substance which has proven useful in the treatment and prophylaxis of viral infections, in treating symptoms of Parkinson's disease, cocaine dependence, and apathy in multiple sclerosis."6.69Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. ( Beelitz, G; Berghöfer, A; Bode, L; Brodhun, B; Ferszt, R; Kühl, KP; Ludwig, H; Müller-Oerlinghausen, B; Severus, EW; Winzer, B, 1999)
"Among them, depression is a common psychiatric symptom, and links to poorer recovery."5.42Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. ( Chen, Y; Duanmu, W; Feng, H; Fu, C; Ge, H; Hu, R; Liu, X; Sui, J; Tan, L; Tang, J, 2015)
"Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily."5.26Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979)
" Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium."4.79Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. ( Camicioli, R; Ganzini, L; Young, BK, 1997)
" The drug does not possess an antidepressant action proper but activates the aggressive-defensive behaviour in experimental reserpine depression and reduces the provocation-induced aggressive behaviour in experimental haloperidol depression."3.66[Psychopharmacologic spectrum of melanostatin]. ( Klusha, VE; Kozlovskaia, MM; Svirskis, ShV; Val'dman, AV, 1980)
"Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months."3.65Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972)
"Amantadine was not superior to placebo."2.72Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006)
"Amantadinesulfate is a well known substance which has proven useful in the treatment and prophylaxis of viral infections, in treating symptoms of Parkinson's disease, cocaine dependence, and apathy in multiple sclerosis."2.69Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. ( Beelitz, G; Berghöfer, A; Bode, L; Brodhun, B; Ferszt, R; Kühl, KP; Ludwig, H; Müller-Oerlinghausen, B; Severus, EW; Winzer, B, 1999)
"Amantadine treatment was used as an antidepressant and antiviral compound."2.69Word recognition memory before and after successful treatment of depression. ( Dietrich, DE; Emrich, HM; Hauser, U; Huber, TJ; Johannes, S; Kipp, K; Kleinschmidt, A; Schneider, U; Spannhuth, CW; Wieringa, BM, 2000)
"Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions."2.48Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012)
"Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1."2.41Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001)
"After the onset of Parkinson's disease, depression is very common."2.37Parkinson's disease in the elderly: psychiatric manifestations. ( Fonda, D, 1985)
"Among them, depression is a common psychiatric symptom, and links to poorer recovery."1.42Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. ( Chen, Y; Duanmu, W; Feng, H; Fu, C; Ge, H; Hu, R; Liu, X; Sui, J; Tan, L; Tang, J, 2015)
"In patients who had impulse control disorders at baseline (n = 119), high dopamine agonist dose was associated with the presence of disorders at follow-up."1.38Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. ( Joutsa, J; Kaasinen, V; Martikainen, K; Vahlberg, T, 2012)
"At a 1985 conference on influenza control organised by the US Centers for Disease Control, a major viewpoint expressed was for the routine immunisation of children who are household contacts of high-risk persons."1.27A perspective on influenza control. ( Imperato, PJ, 1986)
"Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily."1.26Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979)

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-199027 (61.36)18.7374
1990's5 (11.36)18.2507
2000's5 (11.36)29.6817
2010's6 (13.64)24.3611
2020's1 (2.27)2.80

Authors

AuthorsStudies
Maratha, S1
Sharma, V1
Walia, V1
Tan, L1
Ge, H1
Tang, J1
Fu, C1
Duanmu, W1
Chen, Y1
Hu, R1
Sui, J1
Liu, X1
Feng, H1
Minozzi, S2
Amato, L2
Pani, PP2
Solimini, R2
Vecchi, S2
De Crescenzo, F1
Zuccaro, P2
Davoli, M2
Yu, M1
Zhang, Y1
Chen, X1
Zhang, T1
Joutsa, J1
Martikainen, K1
Vahlberg, T1
Kaasinen, V1
Induruwa, I1
Constantinescu, CS1
Gran, B1
Iwasaki, Y1
Iguchi, H1
Ichikawa, Y1
Igarashi, O1
Kawabe, S1
Kiyozuka, T1
Maruyama, M1
Ikeda, K1
Fujioka, T1
Garssen, MP1
Schmitz, PI1
Merkies, IS1
Jacobs, BC1
van der Meché, FG1
van Doorn, PA1
Bonelli, RM1
Hofmann, P1
Val'dman, AV1
Kozlovskaia, MM1
Klusha, VE1
Svirskis, ShV1
Jörg, J1
Danielczyk, W2
Moryl, E1
Danysz, W1
Quack, G1
Young, BK1
Camicioli, R1
Ganzini, L1
Huber, TJ2
Dietrich, DE2
Emrich, HM2
Ferszt, R1
Kühl, KP1
Bode, L1
Severus, EW1
Winzer, B1
Berghöfer, A1
Beelitz, G1
Brodhun, B1
Müller-Oerlinghausen, B1
Ludwig, H1
Kleinschmidt, A1
Hauser, U1
Schneider, U1
Spannhuth, CW1
Kipp, K1
Wieringa, BM1
Johannes, S1
Krupp, LB1
Christodoulou, C1
McFarland, HR1
Agnoli, A1
Ruggieri, S1
Casacchia, M1
Müller, HF1
Dastoor, DP1
Klingner, A1
Cole, M1
Boillat, J1
Mindham, RH1
Marsden, CD1
Parkes, JD1
Couto, B1
Oliveira, C1
Mattos, JP1
Freitas, MR1
Lipper, S1
Bermanzohn, PC1
Ziedonis, DM1
Kosten, TR1
Imperato, PJ1
Fonda, D1
Vale, S1
Espejel, MA1
Dominguez, JC1
Swash, M1
Roberts, AH1
Zakko, H1
Heathfield, KW1
Brogden, RN1
Speight, TM1
Avery, GS1
Ambrozi, L1
Birkmayer, W1
Neumayer, E1
Riederer, P1
Ananth, J1
Ruskin, R1
Schwab, RS1
Poskanzer, DC1
England, AC1
Young, RR1
Reveno, WS2
Bauer, RB2
Rosenbaum, H2
Gehlen, W1
Kudashov, NI1
Vernier, VG1
Harmon, JB1
Stump, JM1
Lynes, TE1
Marvel, JP1
Smith, DH1
Rizzo, M1
Morselli, PL1
Barbieri, NF1
Megna, GF1
Micalizzi, V1
Pigneri, MT1
Puca, FM1
Schwieger, AC1
Jenkins, AC1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093]40 participants (Anticipated)Observational2022-04-30Not yet recruiting
Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020]100 participants (Anticipated)Interventional2015-12-31Recruiting
A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162]Early Phase 120 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial[NCT03336541]Phase 464 participants (Actual)Interventional2017-11-23Completed
A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders[NCT00344682]Phase 431 participants (Actual)Interventional2006-06-30Completed
Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307]Phase 239 participants (Actual)Interventional2004-06-30Completed
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551]Phase 3223 participants (Actual)Interventional2014-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hamilton Anxiety Rating Scale (HARS)

Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Scores > 30 indicate severe anxiety. (NCT00344682)
Timeframe: baseline & week 8

Interventionunits on a scale (Mean)
Placebo-4.13
Memantine-5.53

Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR)

The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 & 8. (NCT00344682)
Timeframe: baseline & week 8

Interventionunits on a scale (Mean)
Placebo-3.69
Memantine-6.47

Montgomery-Asberg Depression Rating Score (MADRS)

Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures. (NCT00344682)
Timeframe: baseline and week 8

Interventionunits on a scale (Mean)
Placebo-10.75
Memantine-7.13

Montgomery-Asberg Depression Rating Score (MADRS)

Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure. (NCT00344682)
Timeframe: Baseline & week 8

Interventionunits on a scale (Mean)
Placebo-7.25
Memantine-7.13

Montgomery Asberg Depression Rating Scale (MADRS)

The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly

InterventionScore on a scale (Least Squares Mean)
Pramipexole22.629
Escitalopram26.102
Escitalopram and Pramipexole29.455

Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (Parts I-III Combined Scores)

"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).

,,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline at Week 8Change from Baseline at Week 16Change from Baseline at Week 28Change from Baseline at Week 40Change from Baseline at Week 52Change from Baseline at Week 64Change from Baseline at Week 76Change from Baseline at Week 88Change from Baseline at Week 100
ADS-5102 1A41.81.21.64.87.513.28.811.711.311.4
ADS-5102 Group 1P45.6-2.8-1.41.5-0.42.62.67.33.73.7
ADS-5102 Group 252.80.85.76.51.66.16.19.46.46.5
ADS-5102 Group 352.4-5.3-5.2-5.3-4.8-4.6-4.6-4.90.94.1

Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale MDS-UPDRS (Part IV - Motor Complications)

"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).

,,,
Interventionunits on a scale (Mean)
BaselineChange in Baseline from Week 8Change in Baseline from Week 16Change from Baseline at Week 28Change from Baseline at Week 40Change from Baseline at Week 52Change from Baseline at Week 64Change from Baseline at Week 76Change from Baseline at Week 88Change from Baseline at Week 100
Group 1a6.5-0.2-0.8-0.30.00.20.40.90.40.4
Group 1P9.6-3.4-3.2-3.3-2.8-2.9-3.3-2.9-2.8-2.4
Group 29.8-3.6-1.1-1.4-2.9-2.5-1.9-2.7-3.7-3.6
Group 310.4-4.0-3.9-4.4-4.7-3.6-2.5-3.7-4.3-3.6

Number of Participants With Reported AEs and Safety-Related Study Drug Discontinuations

The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks

,,,
InterventionParticipants (Count of Participants)
AEStudy drug-related AESAEsPermanent discontinuation due to AEPermanent discontinuation due to drug-related AEMild AEsModerate AEsMild drug-related AEModerate drug-related AESevere drug-related AE
Group 1a573116124122516123
Group 1P7045212115133615237
Group 223166643133121
Group 355321710811265225

Reviews

12 reviews available for amantadine and Depression

ArticleYear
Dopamine agonists for the treatment of cocaine dependence.
    The Cochrane database of systematic reviews, 2015, May-27, Issue:5

    Topics: Amantadine; Antidepressive Agents; Bromocriptine; Cocaine-Related Disorders; Depression; Dopamine Ag

2015
Dopamine agonists for the treatment of cocaine dependence.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Amantadine; Bromocriptine; Cocaine-Related Disorders; Depression; Dopamine Agonists; Humans; Levodop

2011
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
A systematic review of the treatment studies in Huntington's disease since 1990.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:2

    Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Ag

2007
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
    Drugs & aging, 1997, Volume: 10, Issue:5

    Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic

1997
Possible use of amantadine in depression.
    Pharmacopsychiatry, 1999, Volume: 32, Issue:2

    Topics: Amantadine; Animals; Antidepressive Agents; Depression; Depressive Disorder; Dopamine Agents; Humans

1999
Fatigue in multiple sclerosis.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3

    Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste

2001
Parkinson's disease in the elderly: psychiatric manifestations.
    Geriatrics, 1985, Volume: 40, Issue:4

    Topics: Aged; Amantadine; Depression; Humans; Levodopa; Mood Disorders; Parasympatholytics; Parkinson Diseas

1985
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
    Drugs, 1971, Volume: 2, Issue:4

    Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia Diseases; Brain Che

1971
[Biochemical aspects of human behavior].
    Wiener Zeitschrift fur Nervenheilkunde und deren Grenzgebiete, 1973, Volume: 31, Issue:3

    Topics: Amantadine; Behavior; Biogenic Amines; Brain; Depression; Dihydroxyphenylalanine; Dopamine; Epinephr

1973
Use of drugs in the treatment of parkinsonism.
    Nutrition reviews, 1970, Volume: 28, Issue:1

    Topics: Amantadine; Depression; Dihydroxyphenylalanine; Feeding and Eating Disorders; Humans; Hypertension;

1970
[Use of amantadine in the prevention and treatment of influenza (review of the literature)].
    Voprosy okhrany materinstva i detstva, 1971, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Amantadine; Animals; Chick Embryo; Child; Cycloparaffins; Depression; Female; Hem

1971

Trials

9 trials available for amantadine and Depression

ArticleYear
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.
    Journal of neurology, neurosurgery, and psychiatry, 2006, Volume: 77, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Anxiety; Cross-Over Studies; Depressio

2006
Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection.
    Pharmacopsychiatry, 1999, Volume: 32, Issue:4

    Topics: Amantadine; Analysis of Variance; Antidepressive Agents; Antiviral Agents; Borna Disease; Chronic Di

1999
Word recognition memory before and after successful treatment of depression.
    Pharmacopsychiatry, 2000, Volume: 33, Issue:6

    Topics: Adult; Aged; Amantadine; Antidepressive Agents; Antiviral Agents; Borna Disease; Cross-Over Studies;

2000
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
    Pharmacology, 1978, Volume: 16 Suppl 1

    Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depressio

1978
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
    Psychological medicine, 1976, Volume: 6, Issue:1

    Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug;

1976
The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
    Neurologia, neurocirugia, psiquiatria, 1976, Volume: 17, Issue:4

    Topics: Amantadine; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Drug Therapy, Com

1976
Depression as a prognostic factor for pharmacological treatment of cocaine dependence.
    Psychopharmacology bulletin, 1991, Volume: 27, Issue:3

    Topics: Adult; Amantadine; Cocaine; Depression; Desipramine; Female; Humans; Male; Prognosis; Psychiatric St

1991
A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1987, Volume: 14, Issue:3

    Topics: Activities of Daily Living; Adult; Amantadine; Clinical Trials as Topic; Depression; Double-Blind Me

1987
Amantadine in depression.
    Lancet (London, England), 1971, Aug-21, Volume: 2, Issue:7721

    Topics: Amantadine; Central Nervous System; Depression; Evaluation Studies as Topic; Female; Humans; Male

1971

Other Studies

23 other studies available for amantadine and Depression

ArticleYear
Possible involvement of NO-cGMP signaling in the antidepressant like Effect of Amantadine in mice.
    Metabolic brain disease, 2022, Volume: 37, Issue:6

    Topics: Amantadine; Animals; Antidepressive Agents; Cyclic GMP; Depression; Glutamic Acid; Hindlimb Suspensi

2022
Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats.
    Behavioural brain research, 2015, Feb-15, Volume: 279

    Topics: Amantadine; Animals; Antidepressive Agents; Apoptosis; Brain Injuries; Corpus Striatum; Depression;

2015
Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress.
    Stress (Amsterdam, Netherlands), 2016, Volume: 19, Issue:1

    Topics: Amantadine; Animals; Antidepressive Agents; Blotting, Western; CA1 Region, Hippocampal; Cognition; C

2016
Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Parkinsonism & related disorders, 2012, Volume: 18, Issue:10

    Topics: Aged; Amantadine; Antidepressive Agents; Antiparkinson Agents; Data Collection; Depression; Disease

2012
Fatigue and depression are associated with poor quality of life in ALS.
    Neurology, 2003, Sep-23, Volume: 61, Issue:6

    Topics: Adaptation, Psychological; Amantadine; Amyotrophic Lateral Sclerosis; Caregivers; Cross-Sectional St

2003
[Psychopharmacologic spectrum of melanostatin].
    Biulleten' eksperimental'noi biologii i meditsiny, 1980, Volume: 89, Issue:6

    Topics: Aggression; Amantadine; Animals; Behavior, Animal; Biogenic Amines; Brain Chemistry; Catalepsy; Cats

1980
[Therapeutic concept in Parkinson disease].
    Deutsche medizinische Wochenschrift (1946), 1983, Jul-15, Volume: 108, Issue:28-29

    Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocri

1983
[Crises in the course of Parkinson's disease].
    Wiener medizinische Wochenschrift (1946), 1980, Feb-29, Volume: 130, Issue:4

    Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson

1980
Potential antidepressive properties of amantadine, memantine and bifemelane.
    Pharmacology & toxicology, 1993, Volume: 72, Issue:6

    Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera

1993
Potential antidepressive properties of amantadine, memantine and bifemelane.
    Pharmacology & toxicology, 1993, Volume: 72, Issue:6

    Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera

1993
Potential antidepressive properties of amantadine, memantine and bifemelane.
    Pharmacology & toxicology, 1993, Volume: 72, Issue:6

    Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera

1993
Potential antidepressive properties of amantadine, memantine and bifemelane.
    Pharmacology & toxicology, 1993, Volume: 72, Issue:6

    Topics: Amantadine; Analysis of Variance; Animals; Antidepressive Agents; Benzhydryl Compounds; Body Tempera

1993
Treating parkinsonism in the era of levodopa.
    American family physician, 1975, Volume: 12, Issue:3

    Topics: Amantadine; Antidepressive Agents; Anxiety; Depression; Histamine H1 Antagonists; Humans; Levodopa;

1975
Amantadine in senile dementia: electroencephalographic and clinical effects.
    Journal of the American Geriatrics Society, 1979, Volume: 27, Issue:1

    Topics: Administration, Oral; Aged; Amantadine; Anxiety; Dementia; Depression; Electroencephalography; Femal

1979
Letter: Electroconvulsive therapy in patients with parkinsonism.
    The American journal of psychiatry, 1975, Volume: 132, Issue:4

    Topics: Amantadine; Atropine; Depression; Diphenhydramine; Electroconvulsive Therapy; Female; Humans; Levodo

1975
A perspective on influenza control.
    Lancet (London, England), 1986, Mar-29, Volume: 1, Issue:8483

    Topics: Adult; Aged; Amantadine; Child; Depression; Female; Health Occupations; Humans; Influenza A virus; I

1986
Treatment of involuntary movement disorders with tetrabenazine.
    Journal of neurology, neurosurgery, and psychiatry, 1972, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Aged; Amantadine; Child; Depression; Dystonia Musculorum Deformans; Evaluation St

1972
Treatment of intractable depression.
    International pharmacopsychiatry, 1974, Volume: 9, Issue:4

    Topics: Amantadine; Antidepressive Agents; Depression; Dextroamphetamine; Drug Therapy, Combination; Hormone

1974
Amantadine in Parkinson's disease. Review of more than two years' experience.
    JAMA, 1972, Nov-13, Volume: 222, Issue:7

    Topics: Aged; Amantadine; Ataxia; Constipation; Depression; Diarrhea; Dihydroxyphenylalanine; Drug Synergism

1972
L-dopa for parkinsonism.
    Geriatrics, 1973, Volume: 28, Issue:1

    Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Follow-Up Studies; Hallucinations; Hum

1973
[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].
    Archiv fur Psychiatrie und Nervenkrankheiten, 1974, Apr-09, Volume: 218, Issue:4

    Topics: Amantadine; Anesthetics; Anti-Bacterial Agents; Antidepressive Agents; Antihypertensive Agents; Anti

1974
The toxicologic and pharmacologic properties of amantadine hydrochloride.
    Toxicology and applied pharmacology, 1969, Volume: 15, Issue:3

    Topics: Abnormalities, Drug-Induced; Acetylcholine; Amantadine; Analgesia; Animals; Arrhythmias, Cardiac; Bl

1969
Amantadine-induced aggressiveness.
    British medical journal, 1972, Jul-01, Volume: 3, Issue:5817

    Topics: Aged; Aggression; Amantadine; Depression; Humans; Motor Activity

1972
L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Geriatrics, 1971, Volume: 26, Issue:8

    Topics: Aged; Amantadine; Chlorides; Depression; Dihydroxyphenylalanine; Drug Hypersensitivity; Female; Foll

1971
[Preliminary psychological findings during treatment of the parkinsonian syndrome with amantadine. Preliminary observations].
    Minerva medica, 1971, Oct-31, Volume: 62, Issue:82

    Topics: Amantadine; Anxiety; Depression; Dihydroxyphenylalanine; Emotions; Humans; Intelligence Tests; Menta

1971
Observations on the effect of amantadine hydrochloride in the treatment of Parkinsonism.
    The Medical journal of Australia, 1970, Oct-03, Volume: 2, Issue:14

    Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Muscle Tonu

1970